DOI:
10.1055/s-00000059
Pneumologie
LinksClose Window
References
Seto T, Kato T, Nishio M. et al.
Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.
Lancet Oncol 2014;
15: 1236-1244
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.